500 documents showing 301–360

May 23, 2019

Spruce Point Capital

Verint Systems, Inc. VRNT

Verint's reported 8% growth is a mirage of M&A, FX and ASC 606 tailwinds masking negative organic growth; rerate to BPO peer multiples for 60-70% downside to $17-25.

N4 V3

May 16, 2019

Spruce Point Capital

A.O. Smith Corporation AOS

A.O. Smith's China growth is cracking while revenue-recognition red flags, unsustainable 40%+ margins and vanishing insider ownership point to 45-65% downside to $17.75-$27.30.

N4 V3

May 07, 2019

Spruce Point Capital

Kornit Digital Ltd. KRNT

Kornit's 2018 boom was an Amazon warrant-and-rebate illusion — 105% of cash flow came from one customer, a scandal-tainted CFO is covering it, leaving 75-85% downside to $4.50-$9.30.

N5 V3

Apr 30, 2019

Spruce Point Capital

PetIQ, Inc. PETQ

PetIQ's grey-market vet-drug margins and rebate-dependent earnings are unsustainable as Merial goes direct-to-retail, while a $200M wellness-center cash burn and the CEO's Petters/Fleming ties imply 75-90% downside.

N5 V3

Apr 09, 2019

Spruce Point Capital

Aerojet Rocketdyne Holdings, Inc. AJRD

AJRD's rocket franchise is eroding as Blue Origin and SpaceX displace it; aggressive accounting and ~$900M ignored liabilities mask 5x leverage and 40-60% downside to $13-$20.

N4 V3

Mar 21, 2019

Spruce Point Capital

Dexcom, Inc. DXCM

Dexcom's blow-out growth is a sugar high — driven by hidden price hikes and sensor stockpiling — and Abbott's cheap Libre 2 will commoditize CGMs, taking DXCM down 45-60% to $65-$85.

N4 V3

Mar 18, 2019

Starboard Value

Bristol-Myers Squibb BMY

BMY is overpaying ~$30B for Celgene's risky pipeline, betting on 10 blockbusters in 8 years vs 3 in 15; shareholders should vote against and unlock 900bps of standalone margin upside.

N5 V3

Mar 01, 2019

Starboard Value

Bristol-Myers Squibb BMY

BMY's $91B Celgene deal bets the company on a REVLIMID patent cliff and pipeline requiring 10 blockbusters in 8 years — shareholders should vote no and pursue a standalone Amgen-style transformation.

N5 V3

Mar 01, 2019

Elliott Management

Telecom Italia TIT.MI

Vivendi destroyed value at TIM during its control; shareholders must reject Bolloré's nominees at the March 29 AGM and keep the independent board.

N5 V4

Mar 01, 2019

Spruce Point Capital

Carvana Co. CVNA

Carvana is a CCC+-rated subprime used-car dealer masquerading as a tech disruptor; Spruce Point sees 56-83% downside to $7.50-$19.60, with a credible path to zero.

N4 V3

Feb 28, 2019

Starboard Value

Bristol-Myers Squibb Company BMY

Bristol-Myers' $91bn Celgene acquisition buys pharma's largest patent cliff; Starboard urges shareholders to vote it down and replace directors to pursue a standalone plan or sale.

N4 V3

Feb 28, 2019

Starboard Value

Bristol-Myers Squibb Company BMY

Starboard urges BMY shareholders to reject the $91B Celgene acquisition — it imports a massive REVLIMID patent cliff and was rushed through without exploring standalone turnaround or a sale of Bristol-Myers.

N4 V3

Feb 22, 2019

Starboard Value

Magellan Health, Inc. MGLN

Magellan destroyed $700M of value through failed acquisitions and three 2018 guidance cuts; Starboard's six-director slate will overhaul the board and run a parallel sale process at peer multiples.

N4 V2

Feb 13, 2019

Pershing Square

Pershing Square Holdings, Ltd. PSH

PSH offers an activist portfolio compounding well above the S&P 500, available at a 27% discount to NAV, with a new dividend, buybacks, and insider buying narrowing the gap.

N3 V3

Feb 08, 2019

Muddy Waters

Inogen, Inc. INGN

Inogen's growth story rests on a fabricated TAM sourced from a plagiarism-riddled WinterGreen report; real market is shrinking, peak sales arrive 2019-2020, target $46 (-67%).

N5 V2

Jan 23, 2019

Spruce Point Capital

Amdocs Limited DOX

Spruce Point sees 25-50% downside in Amdocs (DOX): a Guernsey-domiciled telecom-IT vendor whose steady margins, opaque insider selling via Pines Quest, and dot-com-era accounting tricks signal $30-$45 per share.

N4 V3

Jan 07, 2019

Starboard Value

Dollar Tree, Inc. DLTR

Dollar Tree is deeply undervalued because Family Dollar is a failed acquisition and the $1 price ceiling is a self-imposed cap; selling Family Dollar and testing multi-price points unlocks $150/share.

N4 V2

Dec 13, 2018

Spruce Point Capital

XPO Logistics, Inc. XPO

XPO is a United-Rentals-style roll-up masking financial strain with aggressive accounting and a felon-linked board; normalized EPS is 47% overstated, implying 40–60% downside.

N5 V3

Nov 15, 2018

Carl Icahn

Dell Technologies (Class V / DVMT tracking stock) DVMT

Dell's $109 buyout of the DVMT tracker is really $90 — a 42% discount engineered to transfer $11bn from public holders to Michael Dell and Silver Lake. Vote no.

N4 V3

Oct 31, 2018

Spruce Point Capital

Dollarama Inc. DOL

Dollarama trades 50% above peers as a 'dollar store' now selling $4 goods; reversing FX hedges, Dollar Tree's arrival and governance red flags imply ~40% downside to C$24.60.

N4 V3

Oct 23, 2018

Citron Research

Tesla, Inc. TSLA

After five years short, Citron reverses on Tesla: Model 3 is dominating luxury and EV segments, Munro confirms 30% margins, and worst-case math yields $599/share.

N4 V2

Oct 17, 2018

Spruce Point Capital

Mercury Systems Inc. MRCY

Mercury Systems faces 50-60% downside as Supermicro-hack exposure, missing cyber leadership, hidden A/R factoring, and the sector's richest multiple collide with rising DFARS compliance costs.

N4 V3

Oct 11, 2018

Trian Partners

PPG Industries, Inc. PPG

PPG has underperformed peers by 3,500 bps under CEO McGarry; Trian wants Chuck Bunch reinstalled, the balance sheet levered, and the portfolio split into Architectural and Industrial to unlock ~40% upside.

N4 V3

Oct 09, 2018

Pershing Square

Starbucks SBUX

Starbucks at 22x forward P/E vs. 26x historical average is a rare chance to own a category-killer coffee brand — fixable U.S. SSS and a $14bn buyback reverting the multiple doubles the stock.

N4 V3

Oct 01, 2018

Third Point

Campbell Soup Company CPB

Campbell's incumbent board delivered 19% TSR vs 306% S&P over 20 years; replace the entire board with Third Point's Independent Slate to unlock $52-58/share via turnaround, breakup, or sale.

N5 V4

Sep 26, 2018

Spruce Point Capital

Henry Schein, Inc. HSIC

HSIC's soon-to-spin Vets First Corp is growing far faster than the Street thinks — proprietary data shows 75% install-base growth, driving a $106-126 SOTP target vs. $84 today.

N4 V3

Sep 05, 2018

Spruce Point Capital

Weis Markets, Inc. WMK

Weis Markets is the most expensive U.S. supermarket masking -1-2% organic decline with aggressive accounting and shrinking disclosures; Spruce Point sees 45-65% downside.

N4 V3

Aug 28, 2018

Citron Research

Wayfair W

Wayfair's unit economics are deteriorating — loss per new customer nearly doubled to $19 — while the stock defies gravity; Citron is re-shorting with a first stop at $100.

N3 V2

Aug 07, 2018

Spruce Point Capital

Maxar Technologies MAXR

Maxar's MDA-DigitalGlobe merger masks a collapsing satellite cycle and the most aggressive accounting Spruce Point has ever seen, leaving 5.8x-levered MAXR with 100% downside risk.

N5 V3

Jul 19, 2018

Spruce Point Capital

2U, Inc. TWOU

2U's one-size-fits-all OPM model is being disrupted by lower-take-rate fee-for-service rivals; FOIA-documented program failures imply 30-50% downside to $47-$65/share.

N4 V3

Jul 01, 2018

Third Point

Nestlé S.A. NESN

Nestlé has been too slow to adapt to a changing consumer industry; adopting a #NestléNOW mindset — sharper strategy, bolder portfolio divestitures including the L'Oréal stake, and a three-division split — can double EPS by 2022.

N5 V4

Jun 27, 2018

Spruce Point Capital

Momo, Inc. MOMO

Momo's 'blowout' live-video numbers hide a SAIC fraud charge, 123 undisclosed VIE subs, an illegal gambling site, and a fading KOL base — 30-50% downside to $23-$32.

N4 V3

Jun 07, 2018

Spruce Point Capital

Healthcare Trust of America, Inc. HTA

HTA's suspiciously flat Same-Property NOI growth mirrors Brixmor's pre-restatement pattern; Spruce Point sees 20-40% downside to $15-$20 once the accounting unravels.

N5 V3

May 31, 2018

Citron Research

Snap Inc. SNAP

SNAP is the cheapest social stock at 3x sales with 21% short interest, dominant teen mindshare and Tencent backing — upside to $17 as shorts cover.

N4 V2

May 24, 2018

Carl Icahn

SandRidge Energy SD

SandRidge trades at a ~45% discount to its own PV-10 because the post-bankruptcy 'bankruptcy board' destroys value via dilutive deals; replace it with Icahn's slate to run a real sale process.

N4 V3

May 17, 2018

Spruce Point Capital

U.S. Concrete Inc USCR

USCR's 21% gross margins and Adj EBITDA growth are engineered via capital leases and overcapitalized truck costs; CEO Sandbrook should resign and shares face 60-90% downside to $6-$25.

N4 V3

May 10, 2018

Land & Buildings

Taubman Centers, Inc. TCO

Taubman's persistent peer underperformance stems from a family-entrenched board and dual-class structure; electing Litt and collapsing Series B shares unlocks value common shareholders have been denied.

N4 V3

May 07, 2018

Elliott Management

athenahealth, Inc. ATHN

Elliott offers $160/share cash for athenahealth — a 27% premium valuing the company at ~$6.9bn — arguing chronic execution failures make going private the only path to realizing its HCIT potential.

N4 V2

Apr 23, 2018

Elliott Management

Hyundai Motor Group

HMG's Mobis-Glovis spinoff is suboptimal; a true holding-company structure plus KRW 6tn buybacks, a 40-50% payout, and independent boards close peer discounts and deliver 15%+ upside.

N5 V4

Apr 23, 2018

Greenlight Capital

Assured Guaranty AGO

Assured Guaranty is a melting-ice-cube bond insurer aggressively returning capital it hasn't earned; Puerto Rico losses alone (2-4x reserves) will force a capital raise or strip the AA rating it needs to write new business.

N5 V2

Apr 17, 2018

Carl Icahn

Xerox Corporation XRX

Xerox's CEO is handing 50.1% control to Fuji 'without spending a penny' for ~$28/share; vote down the deal and replace the board to unlock $54-$64 standalone.

N5 V3

Apr 11, 2018

Starboard Value

Newell Brands Inc. NWL

Newell's board destroyed $10bn and handed control to Icahn; elect Starboard's four independent nominees to execute a credible divestiture plan and restore accountability.

N4 V2

Apr 05, 2018

Elliott Management

Telecom Italia SpA (TIM) TIT.MI

TIM's operating turnaround is real, but Vivendi-controlled governance has tripled the peer discount; independent directors plus NetCo separation could double the stock to €1.6.

N5 V4

Apr 04, 2018

Spruce Point Capital

Globant SA GLOB

Globant is a poorly organized digital-IT roll-up using accounting games and Luxembourg disclosure loopholes to mask decelerating organic growth; shares warrant 40-50% downside to $24.50-$29.50.

N4 V3

Apr 02, 2018

Carl Icahn

Commvault Systems, Inc. CVLT

Commvault is a product-great but company-broken data management software leader; Elliott (10.3%) demands an operational review, four new directors, and a capital-return program to close a deep valuation discount.

N4 V2

Apr 02, 2018

Elliott Management

Commvault Systems, Inc. CVLT

Commvault, a product-respected software leader, trades at half the peer multiple because of 1,200bps of margin collapse and 20-year stale governance; a board refresh, operational review and capital return will close the gap.

N4 V2

Apr 01, 2018

Kerrisdale Capital

The St. Joe Company JOE

St. Joe's Florida Panhandle land bank is worth a fraction of what bulls claim; absent the promised population boom, the stock is materially overvalued and a short.

N4 V3

Mar 16, 2018

Spruce Point Capital

Kratos Defense & Security Solutions KTOS

Kratos is an overhyped drone play run by executives tied to the Titan FCPA scandal; with the weakest margins in defense and a recent Director fraud indictment, we see 40%-70% downside.

N4 V3

Feb 12, 2018

Starboard Value

Newell Brands Inc. NWL

Starboard, backed by Jarden's founders, seeks to replace Newell's board after CEO Michael Polk destroyed $11bn of value following the 2016 Jarden merger.

N4 V2

Feb 07, 2018

Spruce Point Capital

Realty Income Corp O

Realty Income's 'magic dividend' flywheel is broken — true same-store rents are -0.8% (not +1.2%), and as rates rise and tenants disintermediate the stock re-rates 30-45% lower to $28-$35.

N4 V3

Feb 05, 2018

Starboard Value

Mellanox Technologies, Ltd. MLNX

Mellanox insiders have sold $130M of stock across 373 trades vs. one purchase since IPO — evidence the Board lacks confidence in its own plan and must be reconstituted.

N4 V3

Jan 29, 2018

Pershing Square

Pershing Square Holdings (fund-level portfolio update) PSH

After a fourth losing year driven by Valeant and Herbalife, Pershing Square has downsized, returned to core principles, and offers PSH investors an attractive reset entry point.

N3 V3

Jan 25, 2018

Spruce Point Capital

Ballard Power Systems BLDP

Ballard's 167% 2017 rally rests on a fragile China fuel-cell story with weak partners and zero insider skin; expect a repeat of the Azure failure and 35-70% downside to $1.15-$2.50.

N4 V3

Jan 08, 2018

Starboard Value

Mellanox Technologies, Ltd. MLNX

Mellanox has industry-leading 70%+ gross margins but dead-last operating margins among fabless semis; disciplined cost cuts can close a multi-year peer gap and rerate the stock.

N4 V3

Nov 13, 2017

Land & Buildings

Taubman Centers TCO

Taubman's dominant Class A malls are still bustling and growing, yet TCO is down 25% YTD — management, not 'dead malls,' is the problem, with 50%+ upside if the board acts.

N4 V3

Nov 01, 2017

Marcato

Deckers Outdoor Corporation DECK

Deckers' board missed every margin target and wasted $600m on retail bloat and Sanuk; replacing them enables UGG focus, non-core divestitures and a doubling to $135-158.

N4 V3

Sep 21, 2017

Trian Partners

The Procter & Gamble Company PG

P&G's rebuttal deck is riddled with 50+ data errors designed to discredit Peltz; the real issue is ongoing market-share losses and bottom-quartile TSR that only a board seat can fix.

N4 V3

Sep 06, 2017

Trian Partners

The Procter & Gamble Company PG

P&G's insular board and suffocating matrix have driven a decade of share loss; adding Nelson Peltz as one of 11 directors — Heinz/Mondelez/Wendy's tested — would revitalize the $65bn giant.

N4 V3

Sep 06, 2017

Trian Partners

The Procter & Gamble Company PG

P&G's long-tenured Board has rewarded a decade of market-share loss and bottom-quartile EPS growth; electing Nelson Peltz adds the shareholder voice needed to fix innovation, productivity, M&A and governance.

N5 V4

Sep 01, 2017

Trian Partners

Automatic Data Processing (ADP) ADP

ADP has delivered 203% TSR under CEO Rodriguez; Pershing Square owns just 2% of common stock and its nominees lack the HCM and technology experience to improve on this trajectory.

N4 V3